Simón M, Iborra MA, Carrilero B, et al. - Given that Chagas disease has become a global health problem, with the pediatric population being especially vulnerable, researchers conducted this prospective study to characterize the clinical-epidemiologic aspects of disease in this population, as well as tolerance and adherence to treatment and the subsequent evolution of the disease. Participants in the study were 949 children 0–14 years of age screened from 2007 to 2018. According to results, no side effects were identified in ≤ 1-year-old children. Treatment effectiveness and safety in ≤ 1-year-old children were optimum. Increased side effects, the incidence of cardiac and/or digestive disorder and lower effectiveness of treatment were observed in older children, underlining the need for early screening.